Daniel J. Herling, a Member of the Litigation Section of Mintz, Cohn, Ferris, Glovsky and Popeo, P.C., has been appointed Chair of the Drug, Device and Biotechnology Section of the Federation of Defense & Corporate Counsel, Inc. (FDCC).

The FDCC, composed of recognized leaders in the legal community who have achieved professional distinction, is dedicated to promoting knowledge, fellowship, and professionalism of its members as they pursue the course of a balanced justice system and represent those in need of a defense in civil lawsuits.

The Drug, Device & Biotechnology Section includes corporate and defense counsel who are involved in defending (1) FDA-approved and over-the-counter medicines; (2) FDA-approved medical devices; and, (3) biotechnology products of all types. Section members keep abreast of, and disseminate among themselves, information about legal developments and legislative/regulatory enactments relevant to drugs, devices, and biotechnology products. This is done at Section meetings held twice a year in conjunction with the FDCC Annual and winter meetings, as well as through intra-section email communications.

Mr. Herling’s practice is focused on product liability issues relating to pharmaceuticals and medical devices, commercial litigation, and antitrust matters. His trial work also encompasses class actions, intellectual property litigation, patent infringement, and professional liability.

Mr. Herling advises international companies in the pharmaceutical, medical device, food, over-the-counter drugs, homeopathic remedies, and dietary supplement industries. He has served as defense counsel in over 3,000 product liability cases and represented companies in both state and federal courts in California and the US.  Mr. Herling routinely advises clients on regulatory matters as well as the selection of local counsel and lead trial attorneys. His commercial litigation practice has covered a wide spectrum of issues and included representation of several international companies based in Italy, Mexico, India, United Kingdom, Korea, Japan, Taiwan, Germany, Australia, and Switzerland.